AbbVie/$ABBV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Ticker
$ABBV
Sector
Primary listing
NYSE
Industry
Biotechnology
Headquarters
Employees
55,000
ISIN
US00287Y1091
Website
AbbVie Metrics
BasicAdvanced
$322B
77.91
$2.34
0.55
$6.38
3.60%
Price and volume
Market cap
$322B
Beta
0.55
52-week high
$218.66
52-week low
$163.52
Average daily volume
6.3M
Dividend rate
$6.38
Financial strength
Current ratio
0.76
Quick ratio
0.485
Long term debt to equity
4,422.845
Total debt to equity
4,789.603
Dividend payout ratio (TTM)
266.46%
Interest coverage (TTM)
6.68%
Profitability
EBITDA (TTM)
27,366
Gross margin (TTM)
70.93%
Net profit margin (TTM)
7.31%
Operating margin (TTM)
32.88%
Effective tax rate (TTM)
-16.04%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
8.34%
Return on equity (TTM)
88.40%
Valuation
Price to earnings (TTM)
77.913
Price to revenue (TTM)
5.621
Price to book
96.79
Price to tangible book (TTM)
-3.49
Price to free cash flow (TTM)
20.959
Free cash flow yield (TTM)
4.77%
Free cash flow per share (TTM)
869.82%
Dividend yield (TTM)
3.50%
Forward dividend yield
3.60%
Growth
Revenue change (TTM)
5.45%
Earnings per share change (TTM)
-30.38%
3-year revenue growth (CAGR)
0.38%
10-year revenue growth (CAGR)
10.87%
3-year earnings per share growth (CAGR)
-30.53%
10-year earnings per share growth (CAGR)
7.65%
3-year dividend per share growth (CAGR)
5.59%
10-year dividend per share growth (CAGR)
13.24%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
Bulls say / Bears say
AbbVie has raised its 2025 profit forecast, driven by strong sales of its newer immunology drugs, Skyrizi and Rinvoq, which significantly exceeded Wall Street expectations. (reuters.com)
The company anticipates that Skyrizi and Rinvoq together will generate over $31 billion in sales by 2027, reinforcing their strategic importance amid Humira’s decline. (reuters.com)
AbbVie has been actively acquiring firms to strengthen its pipeline, including a $8.7 billion deal for Cerevel Therapeutics, enhancing its position in neuroscience. (reuters.com)
AbbVie has revised its 2025 adjusted profit forecast downward due to $248 million in acquisition-related expenses, including milestone payments and research and development costs. (reuters.com)
Sales of Humira, AbbVie's former best-selling rheumatoid arthritis drug, fell 49% to $1.68 billion due to increased competition from cheaper biosimilars. (reuters.com)
AbbVie faces potential financial challenges with a debt-to-equity ratio of 17.94, significantly higher than the industry's average of 0.41, indicating substantial leverage. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Jun 2025.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
AbbVie News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul15
AbbVie
Dividend·Ex-dividend
Aug15
AbbVie
Dividend·Payment
$1.64Per share
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $322B as of June 30, 2025.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 77.91 as of June 30, 2025.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of June 30, 2025, the dividend rate is $6.38 and the yield is 3.6%. AbbVie has a payout ratio of 266.46% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment is scheduled for August 15, 2025.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.